Schisandrin B

Drug Profile

Schisandrin B

Alternative Names: (-) schisandrin B; Sch B

Latest Information Update: 16 Oct 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hong Kong University of Science and Technology; MitoPharm Corporation
  • Developer MitoPharm Corporation
  • Class
  • Mechanism of Action Antioxidants; Mitochondrial protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease; Reperfusion injury

Most Recent Events

  • 16 Oct 2012 Discontinued - Preclinical for Alzheimer's disease in USA (unspecified route)
  • 16 Oct 2012 Discontinued - Preclinical for Reperfusion injury in USA (unspecified route)
  • 22 Jun 2007 Preclinical trials in Reperfusion injury in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top